GSK has signed an eleventh-hour agreement to give Alfasigma rights to its primary biliary cholangitis (PBC) therapy linerixibat, which is under regulatory review in most major pharma markets worldwide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results